- Record: found
- Abstract: not found
- Article: not found
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Warner K Huh ,
Elmar A Joura ,
Anna R Giuliano ,
Ole-Erik Iversen ,
Rosires Pereira de Andrade ,
Kevin A Ault ,
Deborah Bartholomew ,
Ramon M Cestero ,
Edison N Fedrizzi ,
Angelica L Hirschberg ,
Marie-Hélène Mayrand ,
Angela Maria Ruiz-Sternberg ,
Jack T Stapleton ,
Dorothy J Wiley ,
Alex Ferenczy ,
Robert Kurman ,
Brigitte M Ronnett ,
Mark H Stoler ,
Jack Cuzick ,
Suzanne M Garland ,
Susanne K Kjaer ,
Oliver M Bautista ,
Richard Haupt ,
Erin Moeller ,
Michael Ritter ,
Christine C Roberts ,
Christine Shields ,
Alain Luxembourg
November 2017
November 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Primary analyses of a study in young women aged 16-26 years showed efficacy of the
nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58)
vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and
non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent
HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. We aimed to report efficacy of the 9vHPV
vaccine for up to 6 years following first administration and antibody responses over
5 years.